Featured Article
Author: OphthalmologyWeb
Video: Carl Zeiss’ ATLAS® 9000 Corneal Topographer
Featured Article
Next Generation Gene Therapy
PHILADELPHIA – Inspired by earlier successes using gene therapy to correct an inherited type of blindness, investigators from the Perelman School of Medicine at the University of Pennsylvania, are poised to extend their approach to other types of blind…
Peak IOP A Better Predictor Of Visual Field Progression Than Mean Pressure Or Fluctuation
IOP-dependent and IOP-independent risk factors affect visual field progression in patients treated for glaucoma, with peak IOP showing a stronger correlation than mean IOP or pressure fluctuation, a study found.
‘A Sticky Situation’ – Part II
Featured Article
Long-Term Trends Confirm Safety Of Cataract Surgery
“Although there was considerable change in operative technique, this alone may not be the sole reason for the reduction in complications; other factors not measured in this study are likely involved,” the study authors said.
New Test To Screen For Glaucoma Damage
A recent paper published in the Journal of Glaucoma shows a new visual evoked potential (VEP) technique to be a fast, objective method to screen for functional damage in glaucomatous eyes. The technique, called short duration transient VEP (SD-tVEP), s…
Santen Announces The Initiation Of A Multinational Phase III Program Evaluating Sirolimus (DE-109) For The Treatment Of Non Infectious Posterior Uveitis
Santen Inc., announced the initiation of a global Phase 3 clinical study evaluating its investigational drug sirolimus (DE‐109) for the treatment of noninfectious posterior uveitis.
Santen Announces The Initiation Of A Multinational Phase III Program Evaluating Sirolimus (DE-109) For The Treatment Of Non Infectious Posterior Uveitis
Santen Inc., announced the initiation of a global Phase 3 clinical study evaluating its investigational drug sirolimus (DE‐109) for the treatment of noninfectious posterior uveitis.
Santen Announces The Initiation Of A Multinational Phase III Program Evaluating Sirolimus (DE-109) For The Treatment Of Non Infectious Posterior Uveitis
Santen Inc., announced the initiation of a global Phase 3 clinical study evaluating its investigational drug sirolimus (DE‐109) for the treatment of noninfectious posterior uveitis.
Difluprednate: A Novel Steroid for the Eye
Featured Article
Truly Portable Imager Produces Still And Video Images Of The Eye
Mentor, Ohio (June 16, 2011) – For convenient ocular imaging in any setting, Volk Optical’s new truly portable Pictor digital device enables ophthalmic imaging not possible with traditional fixed systems. The Pictor delivers high resolution images of t…
Dense Brunescent Cataracts Present Surgical Challenges
Among the most difficult cases for phacoemulsification is the dense brunescent cataract. Due to the increased nuclear density, the cataract surgery requires more effort, energy and attention to successfully complete. The patients are at a higher risk f…
Severe Complications From Cataract Surgery Decline
Serious, potentially blinding complications from cataract eye surgery are uncommon, and have been declining since the 1990s, a new U.S. study finds.
DRY EYE: AWARD WINNING TECHNOLOGY SOLVES DILEMMA FOR PATIENTS Ardeo HealthT Licenses New Dry Eye Therapy From Novagali Pharma
Suwanee, GA, USA (June 15, 2011) – Ardeo Health, LLC, a biopharmaceutical development and licensing company, announced today that it has reached an agreement with Novagali Pharma S.A. of Evry, France to license Novagali’s novel Nova23041 dry eye therap…
U.S. Advisers Back Regeneron Eye Drug
A new eye medicine from Regeneron Pharmaceuticals Inc and Bayer AG is safe and effective for treating a common cause of vision loss, a panel of U.S. experts said on Friday.
Regeneron Announces EYLEA (aflibercept Ophthalmic Solution) Receives Unanimous Recommendation For Approval For Treatment Of Wet AMD From FDA Advisory Committee
Regeneron Pharmaceuticals, Inc. today announced that the Dermatologic and Ophthalmic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) has voted unanimously to recommend that the FDA approve EYLEA, also known as VEGF Trap-Eye, for…
Intravitreal Anti-VEGF Improves Vision In Diabetic Macular Edema Patients
Intravitreal pegaptanib resulted in significantly improved vision in patients with diabetic macular edema, making it an effective, well-tolerated treatment option, a study found.
UC San Diego Names Robert N. Weinreb Chair Of Ophthalmology
Robert N. Weinreb, MD – a clinician, surgeon and scientist who is internationally renowned for his work with glaucoma – has been selected as the new chair of the department of Ophthalmology and director of the Shiley Eye Center at the University of Cal…
Video Interview: Pearls for Ophthalmic Practice Building
Featured Article